Clinical Trial Detail

NCT ID NCT01652482
Title A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

rectum adenocarcinoma

colorectal adenocarcinoma

colon adenocarcinoma

Therapies

Cetuximab

Duligotuzumab

Fluorouracil + Irinotecan + Leucovorin

Age Groups: adult

No variant requirements are available.